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Summary
Elevated procoagulant levels have been correlated with increased thrombin generation in vitro and
with increased venous thromboembolism (VTE) risk in epidemiological studies. Thrombin
generation tests are increasingly being employed as a high throughput method to provide a global
measure of procoagulant activity in plasma samples. The objective of this study was to distinguish
the effects of assay conditions [tissue factor (TF), thrombomodulin, platelets/lipids] and factor levels
on thrombin generation parameters, and determine the conditions and parameters with the highest
sensitivity and specificity for detecting elevated factor levels. Thrombin generation was measured
using calibrated automated thrombography (CAT) in corn trypsin inhibitor (CTI)-treated platelet-
free plasma (PFP) and platelet-rich plasma (PRP). Statistical analysis was performed using
logarithms of observed values with analysis of variance that accounted for experiment and treatment.
The relative sensitivity of lag time (LT), time to peak (TTP), peak height and endogenous thrombin
potential (ETP) to elevated factors XI, IX, VIII, X, and prothrombin was as follows: PFP initiated
with 1 pM TF > PFP initiated with 5 pM TF > PRP initiated with 1 pM TF. For all conditions,
inclusion of thrombomodulin prolonged the LT and decreased the peak and ETP; however, addition
of thrombomodulin did not increase the ability of CAT to detect elevated levels of individual
procoagulant factors. In conclusion, CAT conditions differentially affected the sensitivity of
thrombin generation to elevated factor levels. Monitoring the peak height and/or ETP following
initiation of clotting in PFP with 1 pM TF was most likely to detect hypercoagulability due to
increased procoagulant factor levels.
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Thrombin activates platelets, converts fibrinogen to fibrin, and initiates wound healing.
Elevated procoagulant levels are correlated with abnormal thrombin generation in vitro (1–5)
and increased risk of VTE (6–12). For example, prothrombin concentrations >115% of normal
are associated with a 2.1-fold increased VTE risk, and factor VIII concentrations >200% are
associated with markedly elevated VTE risk (OR = 10.8) (6,7). Tests that assess the ability of
plasma to generate thrombin are thought to provide a more global measure of hemostasis and
thrombosis than standard clotting assays. Such tests may be useful for determining risk of
primary and recurrent VTE, and therefore, duration of antithrombotic therapy.
The most commonly used assay for continuous thrombin measurement is calibrated automated
thrombography (CAT) (13). CAT is based on monitoring cleavage of a slow-reacting
fluorogenic substrate and comparing it to a known thrombin concentration added to non-
clotting samples (13). Studies have demonstrated CAT's ability to detect reduced thrombin
generation in clotting factor deficiency (14–17). CAT appears most sensitive to
hypocoagulability when initiated by low (1 pM) TF (16).
Given these findings, it is logical to hypothesise that CAT can be used to detect
hypercoagulability due to elevated factor levels. Using high (184–429 pM) TF and no added
phospholipids, Siegemund et al. observed increased ETP in platelet-poor plasma with high
concentrations of factors XI and IX, but not VIII (4). In contrast, in PRP assays in which clotting
was initiated with low (0.5 pM) TF, Regnault et al. observed increased ETP with elevated
factor VIII (3). Several studies have correlated recurrent VTE risk with elevated peak height
and/or ETP (18–24). However, another study correlated abnormal thrombin generation with
first, but not recurrent VTE (25). It has been proposed that differences in findings from these
studies stem, in part, from variations in assay conditions (25–27). Notably, these studies
differed in the source and concentration of TF and phospholipids, and use (or not) of contact
pathway inhibitors (CTI) and protein C pathway sensitising agents [activated protein C (APC),
thrombomodulin] because the experimental conditions providing the highest sensitivity and
specificity for detecting hypercoagulability have not been defined. The goals of this study were
to:
1. distinguish the effects of assay conditions (added TF, thrombomodulin, platelets/
phospholipids) and elevated factor levels on thrombin generation parameters, and
2. determine the conditions and parameters with the highest sensitivity and specificity
for detecting elevated factor levels.
We simulated “hypercoagulability” by spiking plasma with factors XI, IX, VIII, X, V,
prothrombin, or fibrinogen to 200% and 400% of normal, and measured the effect of these
factors on thrombin generation parameters in different experimental conditions. We report that
the conditions under which CAT was performed differentially affected its sensitivity. Changes
in the peak height and/or ETP following initiation of clotting in PFP with 1 pM TF was most
likely to detect hypercoagulability due to increased factor levels.
Materials and methods
Materials and proteins
All proteins used in this study were of the highest quality and specific activity available. CTI
and factors XI, V, and prothrombin were purchased from Haematologic Technologies, Inc
(Essex Junction, VT). Factor X and plasminogen-, von Willebrand factor- and fibronectin-
depleted fibrinogen were purchased from Enzyme Research Laboratories (South Bend, IN);
factor X was further purified as described (5). Factor VIII (Hemofil M, Baxter, Deerfield, IL)
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and factor IX were the generous gifts of Dr. Dougald M. Monroe (UNC at Chapel Hill). Briefly,
factor IX was prepared from prothrombin complex concentrations by Q Sepharose
chromatography, heparin affinity, metal chelate chromatography using copper, and pseudo-
affinity calcium elution from HiTrap Q. Factor IX could be activated completely by factor XIa
and gave the expected molar concentration when the activated material was titrated with
antithrombin in the presence of heparin. Protein purity was verified by both non-reducing and
reducing 12% SDS-PAGE prior to use. Analysis of factors XI, IX, X, V, prothrombin, and
fibrinogen:
1. revealed only bands of the expected molecular weight for each zymogen and cofactor,
and
2. indicated no activated protein species (data not shown).
The factor VIII preparation (Hemophil M) also contained albumin, however, control
experiments showed no effect of this albumin concentration on thrombin generation (data not
shown). The specific activity of the factor V preparation was 51.3 U/mg, consistent with that
expected for factor V (50–60 U/mg), and ∼40× lower than that expected for factor Va (2000
U/mg), indicating no factor Va contamination in the preparation. Rabbit lung thrombomodulin
was from American Diagnostica, Inc (Stamford, CT). Fluorogenic thrombin substrate (Z-Gly-
Gly-Arg-AMC), TF/Lipid Reagents (PFP-Low, PFP-High), and thrombin calibrator (α2-
macroglobulin/thrombin) were generously provided by Diagnostica Stago (Parsippany, NJ).
Lipids were composed of phosphatidylserine, phosphatidylcholine, and
phosphatidylethanolamine at a ratio of 20:60:20, respectively. Blood was collected according
to protocols approved by the UNC Institutional Review Board.
Plasma preparations
For PFP, blood was collected from 18 healthy individuals [20–45 years old, 50% female, 50%
non-Caucasian, with normal partial thromboplastin times (PTT)] through a 21-gauge needle
into a syringe and immediately transferred to sodium citrate/CTI [0.105 M (3.2%, pH 6.5) and
18.3 μg/mL, respectively] to minimise contact activation (28,29). PFP was prepared by
sequential centrifugation (150 × g, 15 minutes, 13,000 × g, 15 minutes), aliquoted, and snap-
frozen in liquid nitrogen within two hours of phlebotomy. PFPs were then thawed, pooled, and
refrozen for subsequent assays. Pooled PFP was analyzed for levels of factors XI, IX, VIII, X,
V, VII, protein C, free protein S, prothrombin, and fibrinogen at UNC Hospitals McLendon
Clinical Laboratory; all were in the normal reference range.
For PRP, blood was collected from six healthy individuals (21–50 years old, 67% female,
normal PTTs) who had not taken aspirin for two weeks or ibuprofen for three days prior to
phlebotomy. Blood was drawn as for PFP. PRP was prepared by centrifugation (150 × g, 15
minutes) within one hour. The platelet count was measured on a Z1 Series Coulter Counter
(Beckman Coulter, Fullerton, CA), and normalised by dilution with autologous PFP to 225,000/
μl, and used at 150,000/μl (final).
Thrombin generation assay
Factors XI, IX, VIII, X, V, prothrombin or fibrinogen were added to normal, pooled PFP and
individual PRPs to 200% or 400% of normal (final). Thrombin generation was measured by
CAT (13). For PFP experiments, 20 μl of TF/phospholipids were mixed with 80 μl PFP in 96-
well round-bottom microtiter plates (Becton Dickinson, Falcon™). The plate was inserted into
a Fluoroskan Ascent® fluorometer (ThermoLabsystem, Helsinki, Finland) and warmed to 37
°C for 5 minutes. Reactions were initiated by automatically dispensing 20 μl of 2.5 mM
fluorogenic substrate in 0.1 M CaCl2 to each well. Reactions were performed in duplicate or
triplicate in each experiment. The final TF, phospholipid, fluorogenic substrate, and CaCl2
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concentrations were 1 or 5 pM, 4 μM, 416 μM and 16 mM, respectively. Experiments with
PRP were performed under identical conditions, but without added phospholipids. Reactions
were calibrated against wells containing 20 μL of α2-macroglobulin/thrombin complex and 80
μL PFP or PRP (13). Thrombin generation was monitored at 37 °C with excitation and emission
filters at 390 nm and 460 nm, respectively, every 20 seconds for 120 minutes. Experiments
with PFP and 1 pM TF, PFP and 5 pM TF, and PRP and 1 pM TF were performed 10, 5, and
6 times, respectively.
Thrombin parameters were calculated using Thrombinoscope software version 3.0.0.29
(Thrombinoscope BV, Maastricht, Netherlands), which defines the LT as the first time point
after the thrombin concentration exceeds one-sixth peak height, the TTP as the time to the peak
height, the peak height as the maximum thrombin concentration produced, and the ETP as the
time integral of thrombin formation (the area under the thrombin generation curve).
Statistical methods
Statistical analysis was performed for logarithms of parameters using analysis of variance
(ANOVA) that accounted for experiment date (PFP experiments), or donor (PRP experiments)
and elevated factors. Each condition (factor level) was handled separately; factor concentration
was not considered a covariate. An ANOVA model was first fit to each log-transformed
parameter with covariates of date or donor, factor level, an indicator variable for platelets, and
the interaction between factor level and platelet indicator. We compared PFP initiated with 1
pM TF to:
1. PFP initiated with 5 pM TF, and
2. PRP initiated with 1 pM TF.
Hypothesis testing was performed using a contrast matrix corresponding to a 1 degree of
freedom F-test for each parameter. In a separate analysis, for each log-transformed parameter,
a separate ANOVA model was fit with covariates of date or donor and factor level. To
determine the effect of thrombomodulin in the presence of elevated factors, ANOVA models
were applied to the log of the ratio of the parameter value with and without thrombomodulin.
Differences in least square means between conditions and the control were evaluated by t-tests.
Multiple comparisons were handled with Bonferroni corrections; significance was p<0.0033
(0.05/15) unless otherwise indicated. The percent coefficient of variation (%CV) was
calculated as the ratio of the standard deviation to the mean multiplied by one hundred for
inter-assay variability (PFP) and inter-individual variability (PRP).
Results
Thrombin generation in normal PFP and PRP
We first characterised the effects of TF on thrombin generation in normal PFP and PRP.
Thrombin generation in PFP required addition of both TF and phospholipids; omission of either
prevented thrombin generation for >120 minutes (data not shown), indicating that the PFP was
not contaminated with detectable endogenous TF activity, procoagulant lipids, or contact
activation. Similarly, thrombin generation in PRP required addition of TF (data not shown),
indicating that PRP from these healthy subjects did not contain detectable TF activity or contact
activation.
Table 1 shows baseline thrombin generation characteristics for PFP and PRP. Reactions
initiated by 1 and 5 pM TF are indicated: PFP(1 pM TF), PFP(5 pM TF), and PRP(1 pM TF),
respectively. Compared to PFP(1 pM TF), PFP(5 pM TF) demonstrated shortened LT and TTP and
increased peak height and ETP. The inter-assay variability (%CV) of PFP (Table 2) and inter-
individual variability (%CV) in PRP (Table 3) were consistent with prior studies (13,26,30).
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Thrombin generation in PFP(1 pM TF) demonstrated a significantly shorter LT and TTP,
increased peak height and decreased ETP than PRP(1 pM TF), consistent with previous studies
(13,26,30).
Effect of thrombomodulin on thrombin generation in normal PFP and PRP
Thrombin generation in normal PFP is decreased in the presence of thrombomodulin or APC
(3,13,22,24,31,32); however, patients with a protein C pathway deficiency (factor V Leiden,
protein C/S deficiency) have decreased thrombomodulin/APC sensitivity (22,24). Previous
studies have recommended that CAT assays include APC or thrombomodulin to increase
ability to discriminate between healthy subjects and VTE patients, as well as predict VTE
recurrence (19,23,24,31). We first compared thrombin generation in the presence and absence
of thrombomodulin in PFP(1 pM TF) and PFP(5 pM TF) (Fig. 1a, 1b, Table 1). Thrombomodulin
slightly prolonged the LT and reduced the peak height and ETP in both PFP(1 pM TF) and
PFP(5 pM TF). Thrombomodulin slightly shortened the TTP in PFP(1 pM TF), but not
PFP(5 pM TF). Increased TF decreased thrombomodulin sensitivity; that is, 5 nM
thrombomodulin reduced the ETP ∼87±1.9% and ∼28±3.1% for PFP(1 pM TF) and
PFP(5 pM TF), respectively. Thrombomodulin significantly increased the inter-assay %CV of
the peak height and ETP in PFP(1 pM TF), but had less effect in PFP(5 pM TF) (Table 2).
We then examined the impact of thrombomodulin on thrombin generation in PRP(1 pM TF). As
in PFP(1 pM TF), thrombomodulin prolonged the LT and reduced the peak height and ETP in
PRP(1 pM TF) (Fig. 1c, Table 1). In contrast to PFP(1 pM TF), thrombomodulin slightly prolonged
the TTP in PRP(1 pM TF), likely because the TTP in PRP is limited by the time to platelet
activation. These findings are somewhat different, although not altogether inconsistent with
previous findings that thrombomodulin decreased ETP, but did not change LT or TTP in PRP
(13). The subtle differences in response to thrombomodulin in these studies may relate to the
thrombomodulin source (human vs. rabbit lung), although another study found similar effects
of thrombomodulin from different sources on ETP (24). The inter-individual variability
increased for LT and TTP, decreased for ETP, and did not change for peak height in the
presence of thrombomodulin (Table 3). Platelets decreased CAT sensitivity to
thrombomodulin; that is, 5 nM thrombomodulin reduced the ETP ∼66±4.8% in
PRP(1 pM TF), compared to ∼87±1.9% in PFP(1 pM TF) (Fig. 1c,Table 1). The reduced
thrombomodulin sensitivity of PRP versus PFP likely reflects contributions of platelet-derived
factor V(a) to thrombin generation (33,34), and is consistent with previous studies (13).
Effect of procoagulant factors on thrombin generation in PFP and PRP
Finally, we compared the ability to detect hypercoagulability under each of these conditions
(1 and 5 pM TF, in the presence and absence of thrombomodulin, in PFP and PRP). We
measured thrombin generation in PFP and PRP spiked with factors XI, X, IX, VIII, V,
prothrombin, or fibrinogen. We initiated clotting in PFP with 1 or 5 pM TF and 4 μM
phospholipids, and in PRP with 1 pM TF (no phospholipids), in the presence and absence of
thrombomodulin.
LT
The LT in PFP(1 pM TF) and PFP(5 pM TF) were qualitatively similar, although changes in
PFP(5 pM TF) were smaller than changes in PFP(1 pM TF) (Fig. 2a, 2b). In both the absence and
presence of thrombomodulin, intrinsic factors XI, IX, and VIII did not significantly alter the
LT, although effects were slightly greater in the presence of thrombomodulin. Factor X
significantly shortened the LT in both conditions. Interestingly, factor V significantly shortened
the LT in PFP(1 pM TF) but not PFP(5 pM TF). Both prothrombin and fibrinogen significantly
increased the LT, irrespective of the TF concentration or presence of TM. The opposing effects
of factor X and prothrombin on LT in PFP may relate to differences in their plasma
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concentrations. Whereas 200% factor X increases the plasma level from 8 to 16 μg/mL, 200%
prothrombin increases the plasma level from 100 to 200 μg/mL. This high concentration of
prothrombin or the prothrombin activation product fragment 1.2 may competitively inhibit
binding of other Gla proteins to the lipid surface, thereby prolonging the time to complex
assembly and enzyme generation. Indeed, elevated prothrombin did not prolong the LT in
assays performed in the presence of increased (300 μM) lipid concentrations (data not shown).
Procoagulant factors produced unique effects on the LT in PRP(1 pM TF) (Fig. 2c). In both the
presence and absence of thrombomodulin, factors XI, IX, VIII, X, prothrombin, and fibrinogen
non-significantly shortened the LT in PRP(1 pM TF); only 400% factor XI significantly
shortened the LT. These findings suggest that in contrast to PFP, the LT in PRP is predominated
by the time required for platelet activation and supercedes the time necessary to form
procoagulant complexes on exposed lipid. Factor V exhibited a biphasic effect on LT in
PRP(1 pM TF), significantly increasing the LT at 200%, with no effect at 400%. These interesting
observations were unique to experiments with platelets and may reflect differences in the
procoagulant activity of plasma and platelet-derived factor V(a) (34).
TTP
Factors XI, IX, and VIII generally shortened the TTP in PFP(1 pM TF), but did not affect the
TTP in PFP(5 pM TF) (Fig. 3a, 3b). Factor X shortened the TTP in both PFP(1 pM TF) and
PFP(5 pM TF). Factor V and fibrinogen produced little to no effect on TTP in either condition.
With the exception of prothrombin, the factors produced qualitatively similar effects in
PRP(1 pM TF) as in PFP(1 pM TF), with a slight decrease in the TTP with factors XI, IX, VIII, X,
and fibrinogen (Fig. 3c). Effects were similar in the presence and absence of thrombomodulin.
Interestingly, as seen in the LT, whereas prothrombin prolonged the TTP in PFP, it shortened
the TTP in PRP. Again, prothrombin's effect may arise in PFP because of prothrombin binding
to the constitutively exposed lipid surface of the synthetic lipids, whereas the lipid surface is
protected from prothrombin binding on unactivated platelets until the time of activation.
Platelet activation permits simultaneous formation of both tenase and prothrombinase,
preventing inhibition by high prothrombin concentrations.
Peak height
In contrast to effects on LT and TTP, factors exhibited similar effects on peak height in PFP
and PRP; however the magnitude of the effects differed substantially (Fig. 4a-4c). For all
conditions, factors XI, IX, VIII, X, prothrombin, and fibrinogen increased the peak height,
whereas factor V had little effect on peak height. Changes were largest in PFP(1 pM TF), followed
by PFP(5 pM TF) and PRP(1 pM TF), respectively, but similar in the presence and absence of
thrombomodulin for all three conditions.
ETP
As with peak height, factors similarly affected ETP in PFP and PRP; however, the magnitude
of the effects differed substantially with the different conditions (Fig. 5a-5c). Factors IX, VIII,
X, prothrombin, and fibrinogen increased the ETP in PFP(1 pM TF), PFP(5 pM TF), and
PRP(1 pM TF). Factor XI increased ETP only in reactions initiated with 1 pM TF, in the presence
of thrombomodulin. Factor V had little effect on ETP in any condition.
Discussion
Using a range of TF and phospholipid concentrations in the presence and absence of protein
C pathway inhibitors, previous studies have correlated VTE risk with elevated peak height
(18), ETP (20,22–25) or both (19,21). Other studies have focused on the LT, rate, and peak as
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an indicator of circulating TF and prothrombotic disease (19,35,36). Although differences in
findings between studies have been attributed to differences in assay conditions, few studies
have contrasted different assay conditions within a single design, and even fewer under
hypercoagulable conditions. It has not been explicitly shown that all conditions provide equal
sensitivity and specificity to detect hypercoagulability. Given limited plasma sample sizes and
limited availability of samples from large-scale epidemiologic studies of hypercoagulability,
empirical evidence for the use of specific conditions and parameters is essential for designing
prospective studies of plasma hypercoagulability. Our study design permitted the direct
comparison of conditions and parameters to identify those most sensitive and specific to factor-
induced hypercoagulability. To our knowledge, this work is the first comprehensive, systematic
comparison of these conditions in a single study.
Our analysis shows that in PFP, factors XI, IX, VIII, X, prothrombin, and fibrinogen
significantly increased peak height and ETP, though increases were proportionally larger for
peak height than ETP. Whereas the baseline peak height of PFP(5 pM TF) was 74% higher than
that of PFP(1 pM TF) (344 nM vs. 197 nM, respectively, Table 1), the apparent “maximum peak
height” in PFP(5 pM TF) plus elevated factors XI, IX, VIII, X, or V up to 400% was only 23%
higher than that in PFP(1 pM TF) plus elevated factors (396 nM vs. 322 nM, respectively). These
findings suggest that the maximum observable difference between peak height in normal and
“hypercoagulable” PFP was reduced in assays initiated with higher TF (15% for
PFP(5 pM TF) vs. 63% for PFP(1 pM TF). Similarly, the maximum ETP in PFP(5 pM TF) with
elevated factors XI, IX, VIII, X, or V (1925 nM*min) was only 3.8% higher than that in
PFP(1 pM TF) (1854 nM*min). Thus, the maximum observable difference in ETP between PFP
and “hypercoagulable” PFP was reduced in PFP(5 pM TF) (9.7%) versus PFP(1 pM TF) (18%).
This difference is even smaller than that seen for peak height. The exception to these results
is in PFP containing elevated prothrombin. Prothrombin (200%) significantly increased peak
height and ETP in both in both low (1 pM) (1.3-fold and 1.6-fold, respectively) and high (5
pM) (1.4-fold and 1.7-fold, respectively) TF. These findings suggest that the mechanism
limiting thrombin generation in this system results, at least in part, from the prothrombin
concentration and indicates that peak height and ETP are exquisitely sensitive to
hyperprothrombinemia.
It is widely accepted that PRP may provide greater physiologic relevance in assays of this
nature, however studies of PFP persist, in part because of logistical limitations associated with
the use of fresh PRP. Our study demonstrates that CAT assays of PFP and PRP show different
trends in LT and TTP, but provide qualitatively similar data on peak height and ETP. Thus,
studies comparing the presence and absence of platelets are likely to provide consistent
information on peak height and ETP, but inconsistent findings on LT and TTP. Differences in
response of LT or TTP in PFP and PRP may, however, provide important mechanistic
information on the role of platelets and platelet abnormalities in thrombosis.
Epidemiologic studies have correlated elevated levels of factors XI, IX, VIII, X, prothrombin,
or fibrinogen, but not factor V, with increased VTE risk (6–12). In this regard, CAT appears
specific to hypercoagulability due to these factors. It is important to note, however, that the
magnitude of change in thrombin generation did not correlate with the degree of thrombotic
risk associated with each factor. For example, elevated prothrombin produced a large linear
increase in peak height. However, thrombotic risk associated with elevated prothrombin is
relatively small (OR ∼2.1) (7). Discrepancies between the thrombin generation measurements
and clinical risk in the case of elevated prothrombin may result from difficulties in measuring
(pro)thrombin concentrations in excess of the antithrombin level present in the plasma.
Additionally, although 200% fibrinogen increased the peak height and ETP, its role in VTE
risk is controversial. It is unclear whether the effects of fibrinogen on thrombin generation
parameters resulted from changes in thrombin generation, itself, or in the ability of fibrinogen
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(“antithrombin I”) to bind thrombin and preserve its proteolytic activity towards small
molecular substrates. Thus, CAT may demonstrate disproportionately high peak height and
ETP for patients with lower overall risk, reducing the specificity and predictive value of this
technique in certain patients.
As a means of distinguishing effects of procoagulant factors on CAT, we note that whereas
several clotting factors significantly increased peak height and ETP, these factors had different
and sometimes unique effects on other parameters. For example, in PFP(1 pM TF), elevated
levels of factors IX, X, and prothrombin significantly increased peak height and ETP. However,
factor IX did not affect the LT, factor X significantly decreased the LT, and prothrombin
prolonged the LT in low but not high lipid concentrations (data not shown). Thus, analysis of
multiple experimental conditions (e.g., varied lipid concentrations) and/or parameters may be
helpful in discerning factors contributing to abnormal thrombin generation in certain PFPs.
Indeed, Tripodi et al. recently suggested that use of three abnormal thrombin generation
parameters (LT, peak height, and ETP) improves the identification of patients at risk of
recurrent VTE versus analysis based on a single parameter (37).
Comparisons of findings between centers have been difficult, as inter-center variability is high
partly due to the use of “in house” reagents and protocols. Using a particularly elegant study
design, Dargaud et al. (2007) showed that the use of different TF and phospholipid sources
produces large variability in CAT, but standardising conditions significantly reduces center-
to-center variability (27). We used commercially-available reagents from the CAT
manufacturer, which may offer consistency in results and enable the continued evaluation of
these conditions in future studies.
This study has several limitations. First, although thrombomodulin may be helpful in
characterising plasmas with proteins C or S deficiency or factor V Leiden, the physiological
thrombomodulin concentration has not been established because it is primarily a cell-associated
protein. Thus, the concentration of soluble thrombomodulin that provides the most clinically-
useful information has not been determined. Our data suggested that thrombomodulin
increased the inter-assay %CV and dampened the effects of 200% fibrinogen at low TF, but
did not significantly impact the ability to detect hypercoagulability from the other factors tested.
Thus, its general use for detecting protein C pathway abnormalities is compatible with assays
used to detect elevated levels of clotting factors. Second, although epidemiological studies
have suggested elevated levels of certain clotting factors independently increase VTE risk
(6–12), the factor levels we tested were generally higher than those reported in these studies.
Of note, however, prothrombin levels as high as 500% of normal have been reported in patients
with type 2 diabetes (38). CAT's ability to detect elevated prothrombin suggests abnormal
thrombin generation in these patients would be readily detected by this technique. Third, our
study design compared frozen/thawed, pooled PFP with individual PRP, which may emphasise
differences in %CV between PFP and PRP. Fourth, as opposed to tests of individual factor
levels, CAT offers the advantage of testing global haemostatic potential. Effects of multiple
abnormal coagulation factor levels on thrombin generation may be additive, synergistic, or
reflect only the effects of the most limiting factor. Additional studies are warranted to fully
appreciate the effects of multiple factor abnormalities on thrombin generation measured with
this technique. Finally, it is not clear whether CAT recapitulates the in vivo pathologic effects
of procoagulant factors; other mechanisms besides thrombin generation may contribute to
thrombotic risk.
In sum, we have shown that CAT's ability to detect elevated factors varies between factors and
depends on the assay conditions. The largest changes in thrombin generation in response to
elevated factors XI, IX, VIII, X, or prothrombin were seen in peak height and ETP in
PFP(1 pM TF). Smaller changes were observed in PFP(5 pM TF) and PRP(1 pM TF). Therefore,
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monitoring the peak height and/or ETP following initiation of clotting in PFP with 1 pM TF
is most likely to detect hypercoagulability due to increased procoagulant factor levels.
What is known about this topic?
Thrombin generation tests can detect hypocoagulability. Significant interest lies in
determining their ability to detect hypercoagulability.
Previous studies have correlated primary or recurrent VTE risk with abnormal thrombin
generation; however, the experimental conditions differ significantly in these studies.
Standardisation of thrombin generation tests reduces the variability of results and is
necessary for its continued clinical development.
The experimental conditions providing the highest sensitivity and specificity for
detecting hypercoagulability have not been identified.
What does this paper add?
The ability to detect elevated factors varies between factors and depends on the assay
conditions.
The relative sensitivity of lag time (LT), time to peak (TTP), peak height and
endogenous thrombin potential (ETP) to elevated factors XI, IX, VIII, X, and
prothrombin was as follows: PFP initiated with 1 pM TF > PFP initiated with 5 pM TF
> PRP initiated with 1 pM TF.
Monitoring the peak height and/or ETP following initiation of clotting in PFP with 1
pM TF is most likely to detect hypercoagulability due to increased procoagulant factor
levels.
Our findings support efforts to standardise reagents (TF and lipid concentrations) (27) to
reliably achieve the assay conditions necessary for maximal sensitivity. Our data also confirm
effects previously seen in normal plasma, but importantly, extend these findings to
hypercoagulable situations. Identification of conditions that best identify hypercoagulability
and predict VTE warrants further investigation. In vivo, VTE risk likely depends on a
combination of increased procoagulant and decreased anticoagulant activities, and/or other
pathologic mechanisms. In a clinical setting, the concerted use of several different assay
conditions may be necessary to identify patients with distinct clinical phenotypes, not unlike
the use of both aPTT and PT to diagnose factor deficiencies.
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Figure 1. Thrombomodulin decreases thrombin generation in PFP(1 pM TF), PFP(5 pM TF) and
PRP(1 pM TF)
A, B) Thrombin generation in PFP was initiated by addition of 4 μM phospholipids and A) 1
pM TF or B) 5 pM TF. C) Thrombin generation in PRP was initiated by addition of 1 pM TF.
Curves show increasing thrombomodulin: 0 (circles), 2.5 (triangles), 5 (squares), 10
(diamonds), and 20 (crosses) nM, representative of 3 separate experiments.
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Figure 2. Procoagulant factors and thrombomodulin differently influence LT in PFP and PRP
PFP or PRP was spiked with factors XI, IX, VIII, X, V, prothrombin, or fibrinogen to 200%
or 400% of normal. Clotting was initiated by addition of 1 pM TF and 4 μM phospholipids
(circles), 5 pM TF and 4 μM phospholipids (diamonds), or 1 pM TF (no lipids, squares) for
A) PFP(1 pM TF), B) PFP(5 pM TF), and C) PRP(1 pM TF), respectively, in the absence (open
symbols) and presence (closed symbols) of thrombomodulin, as described in methods. Note
y-axis scaling in panel C. The shaded gray box encompasses the 100% value and its standard
error of the mean (SEM). Data show means ±SEM. *p<0.0033 versus 100%.
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Figure 3. Procoagulant factors and thrombomodulin differently influence TTP in PFP and PRP
Reactions were performed as in Fig 2. A) PFP(1 pM TF), B) PFP(5 pM TF), C) PRP(1 pM TF). The
shaded gray box encompasses the 100% value ±SEM. Data show means ±SEM for the absence
(open symbols) and presence (closed symbols) of thrombomodulin. Note y-axis scaling in
panel C. *p<0.0033 versus 100%
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Figure 4. Procoagulant factors and thrombomodulin differently influence peak height in PFP and
PRP
Reactions were performed as in Fig 2. A) PFP(1 pM TF), B) PFP(5 pM TF), C) PRP(1 pM TF). The
shaded gray box encompasses the 100% value ±SEM. Data show means ±SEM for the absence
(open symbols) and presence (closed symbols) of thrombomodulin. Note the y-axis scaling.
*p<0.0033 versus 100%
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Figure 5. Procoagulant factors and thrombomodulin differently influence ETP in PFP and PRP
Reactions were performed as in Fig 2. A) PFP(1 pM TF), B) PFP(5 pM TF), C) PRP(1 pM TF). The
shaded gray box encompasses the 100% value ±SEM. Data show means ±SEM for the absence
(open symbols) and presence (closed symbols) of thrombomodulin. Note the y-axis scaling.
*p<0.0033 versus 100%
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Table 2
Inter-assay variability (%CV) of thrombin generation in PFP
PFP(1 pM TF) PFP(5 pM TF)
-TM +TM -TM +TM
LT 8.4 9.2 10.8 9.8
TTP 6.4 7.0 5.8 5.3
Peak height 15.4 46.8 3.0 7.5
ETP 10.8 45.6 10.0 9.9
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Table 3





Peak height 28.4 29.7
ETP 24.0 15.8
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